NEW YORK (GenomeWeb) – Sygnis said today that it has signed a second contract with Chinese proteomics firm Tanon under which Tanon will sell Sygnis products to the Chinese market.

The deal expands a previous agreement between Sygnis and Tanon covering rights to Sygnis's precast gels. The new deal adds rights to the company's InstantBlue stain for protein detection and its Ultrafast blotting buffer for use in western blotting assays.

Tanon will sell the Sygnis products to the Chinese market under the Tanon name.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Researchers find that a personalized medicine approach could help people who experience pain while taking statins, New Scientist reports.

US National Science Foundation is continuing its responsible research conduct training policy despite its flaws, ScienceInsider reports.

A CRISPR-themed meeting explored how the tool could and should be used, Wired reports.

In Science this week: database of proteins' effects on cancer, targeted error correction sequencing, and more.

Sponsored by

This online, interactive seminar will answer researchers’ most pressing questions about how to gain outstanding research results from proteomic studies.